Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Emplicure
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Product Name : Empli03
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 29, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Emplicure
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buprenorphine,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : MMCAP Infuse
Deal Size : Undisclosed
Deal Type : Agreement
Purdue Pharma Enters Agreement for Low-Cost Opioid Use Disorder Treatment in Prisons
Details : The agreement provides low-cost buprenorphine and naloxone tablets to correctional facilities for opioid use disorder treatment.
Product Name : Suboxone-Generic
Product Type : Controlled Substance
Upfront Cash : Undisclosed
June 05, 2024
Lead Product(s) : Buprenorphine,Naloxone Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : MMCAP Infuse
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Altruix
Deal Size : Undisclosed
Deal Type : Partnership
Altruix Approved to Dispense Brixadi® for Moderate to Severe Opioid Use Disorder
Details : Under the partnership, Altruix has been selected as a limited distribution partner for Brixadi (buprenorphine), an opioid medication and an extended-release subcutaneous injection indicated for the treatment of moderate to severe opioid use disorder pati...
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Undisclosed
August 17, 2023
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Altruix
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Brixadi™ (buprenorphine) injection for SC, will be indicated for the treatment of severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with bupre...
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
May 23, 2023
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Emplicure AB Announce Completion of Phase I PK Study for EMPLI03 with Quotient Sciences
Details : EMPLI03, intended for the treatment of moderate to severe pain. 12 healthy subjects were given a single dose of an oral buccal tablet and blood samples were collected for analysis of Buprenorphine.
Product Name : EMPLI03
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 27, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Quotient Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRIXADI is an investigational, extended-release SC injectable therapy under review by FDA for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 12, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BRIXADI, SC injection, will be indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
February 12, 2022
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Buprenorphine release from the ALA-1000 single injection lasts over 12 weeks with effective concentrations, showing low initial burst without dose dumping effect and good safety and tolerability, including local skin irritation and injection pain sev...
Product Name : ALA-1000
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 03, 2021
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data demonstrate LYN-013 delivered sustained buprenorphine drug levels over one-week dosing period and showed sustained suppression of opioid self-administration in an animal model.
Product Name : LYN-013
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 25, 2021
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Braeburn Resubmits New Drug Application for BRIXADI
Details : BRIXADI is an investigational, extended-release injection for subcutaneous use that is under review by FDA for the treatment of moderate to severe opioid use disorder, and expects to receive a PDUFA date in 30 days.
Product Name : Brixadi
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 15, 2021
Lead Product(s) : Buprenorphine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable